Table 3 Susceptibility of NS5A RAS to NS5B inhibitors and other reagents.

From: Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors

Cell line (OR6c/1B-4)

Sofosbuvir

Interferon-α

Fluvastatin

Oncostatin M

EC50 (nM)

Fold resistance

EC50 (ng/L)

Fold resistance

EC50 (µM)

Fold resistance

EC50 (ng/mL)

Fold resistance

WT

113.3

1.0

48.3

1.0

1.5

1.0

0.9

1.0

Q24K/L28M/R30Q/A92K

79.9

0.7

103

2.1

1.7

1.1

1.5

2.3

Q24K/L28M/R30E/A92K

100.5

0.9

96.2

2.0

2.7

1.8

3.5

3.9

  1. The fold change in resistance was compared with that of the WT.
  2. EC50 effective concentration required to inhibit 50%, WT wild-type, NS nonstructural, RAS resistance-associated substitution.
Back to article page